Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH.

Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.

This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.

LATEST FROM THE BLOG

In Brief: FDA Approves New Drug to Improve Sexual Desire in Women

MGH Center for Women's Mental Health2019-07-10T12:01:16-04:00July 16th, 2019|

The Food and Drug Administration (FDA) has approved a new drug for the treatment of hypoactive sexual desire disorder in premenopausal women. Bremelanotide […]

Behavior Problems More Common In Children with Prenatal Exposure to Valproic Acid

MGH Center for Women's Mental Health2019-07-05T21:22:30-04:00July 15th, 2019|

While we have considerable information regarding the teratogenic risk associated with prenatal exposure to various antiepileptic (AED) drugs, we have less impact on […]

Weekly Roundup for JULY 12, 2019: Recent Publications in Women’s Mental Health

MGH Center for Women's Mental Health2019-07-15T16:53:06-04:00July 13th, 2019|

Although there are data to support the use of many different antidepressants and other psychotropic medications, many women and their providers would prefer […]

Brexanolone (Zulresso) for Postpartum Depression Cleared by the DEA, Now Available

MGH Center for Women's Mental Health2019-07-10T13:54:35-04:00July 11th, 2019|

Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum […]

VIEW ALL RECENT BLOG POSTS

The National
Pregnancy Registry
for Psychiatric Medications:

All pregnant women between the ages of 18-45 with a history of psychiatric illness are eligible to enroll in the registry.

LEARN MORE

MGH Perinatal Depression Scale Mobile App

Are you pregnant? Do you own a smart phone? Get the MGH Perinatal Depression Scale app.

LEARN MORE

RESEARCH STUDIES

A Neurosteroid Intervention for Menopausal and Perimenopausal Depession

Are you experiencing symptoms of menopause and feeling depressed or down? You may be eligible for a research study at Massachusetts General Hospital evaluating how a medication treats menopausal depression and other symptoms of menopause.

National Pregnancy Registry for Psychiatric Medications©

The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, stimulants, and atypical antipsychotics that many women take during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders.

TO PARTICIPATE CALL TOLL-FREE:

1-866-961-2388

MGH Postpartum Psychosis Project (MGHP3)

If you are a mother who has experienced an episode of postpartum psychosis within the past ten years, you could help us to better understand this disorder. Researchers at Massachusetts General Hospital’s (MGH) Ammon-Pinizzotto Center for Women’s Mental Health are announcing the launch of a new research study called the MGH Postpartum Psychosis Project (MGHP3).

VIEW ALL